147 related articles for article (PubMed ID: 35476234)
1. Distribution of gastrointestinal neuroendocrine tumors in Europe: results from a retrospective cross-sectional study.
Loosen SH; Kostev K; Jann H; Tetzlaff F; Tacke F; Krieg S; Knoefel WT; Fluegen G; Luedde T; Krieg A; Roderburg C
J Cancer Res Clin Oncol; 2023 Apr; 149(4):1411-1416. PubMed ID: 35476234
[TBL] [Abstract][Full Text] [Related]
2. Analyses of sex-based clinicopathological differences among patients with gastrointestinal neuroendocrine neoplasms in Europe.
Jann H; Krieg S; Krieg A; Eschrich J; Luedde T; Kostev K; Loosen S; Roderburg C
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7557-7563. PubMed ID: 36971798
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
[TBL] [Abstract][Full Text] [Related]
4. Pattern and risk factors for distant metastases in gastrointestinal neuroendocrine neoplasms: a population-based study.
Cai W; Tan Y; Ge W; Ding K; Hu H
Cancer Med; 2018 Jun; 7(6):2699-2709. PubMed ID: 29733523
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics of 662 patients with pancreatic neuroendocrine tumors receiving antitumoral therapy.
Loosen SH; Kostev K; Eschrich J; Krieg S; Krieg A; Luedde T; Jann H; Roderburg C
Medicine (Baltimore); 2022 Dec; 101(50):e32044. PubMed ID: 36550801
[TBL] [Abstract][Full Text] [Related]
6. [Clinicopathological classification and prognostic factors of gastrointestinal neuroendocrine neoplasms: an analysis of 119 cases].
Ma X; Zhao W; Zhuang C; Wang X; Tu L; Wang M; Sun Y; Cao H
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):997-1001. PubMed ID: 28900989
[TBL] [Abstract][Full Text] [Related]
7. Role of Ki-67 proliferation index in the assessment of patients with neuroendocrine neoplasias regarding the stage of disease.
Miller HC; Drymousis P; Flora R; Goldin R; Spalding D; Frilling A
World J Surg; 2014 Jun; 38(6):1353-61. PubMed ID: 24493070
[TBL] [Abstract][Full Text] [Related]
8. Digestive Neuroendocrine Tumor Distribution and Characteristics According to the 2010 WHO Classification: a Single Institution Experience in Lebanon.
Kourie HR; Ghorra C; Rassy M; Kesserouani C; Kattan J
Asian Pac J Cancer Prev; 2016; 17(5):2679-81. PubMed ID: 27268650
[TBL] [Abstract][Full Text] [Related]
9. Best prognostic factor of neuroendocrine tumors: Grade or Stage? A multidisciplinary single-center study.
Özaslan E; Bayram F; Karaca H; Gürsoy Ş; Öztürk F; Sözüer E; Abdurrezzak Ü; Yurci A; Can Sezgin G; Yıldırım A; Başpınar O; Kula M; Özkan M
Turk J Gastroenterol; 2016 Nov; 27(6):509-514. PubMed ID: 27852541
[TBL] [Abstract][Full Text] [Related]
10. Comparison of World Health Organization 2000/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors.
Pasaoglu E; Dursun N; Ozyalvacli G; Hacihasanoglu E; Behzatoglu K; Calay O
Ann Diagn Pathol; 2015 Apr; 19(2):81-7. PubMed ID: 25702616
[TBL] [Abstract][Full Text] [Related]
11. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE).
Garcia-Carbonero R; Capdevila J; Crespo-Herrero G; Díaz-Pérez JA; Martínez Del Prado MP; Alonso Orduña V; Sevilla-García I; Villabona-Artero C; Beguiristain-Gómez A; Llanos-Muñoz M; Marazuela M; Alvarez-Escola C; Castellano D; Vilar E; Jiménez-Fonseca P; Teulé A; Sastre-Valera J; Benavent-Viñuelas M; Monleon A; Salazar R
Ann Oncol; 2010 Sep; 21(9):1794-1803. PubMed ID: 20139156
[TBL] [Abstract][Full Text] [Related]
12. Clinical course of neuroendocrine tumors with different origins (the pancreas, gastrointestinal tract, and lung).
Kim SJ; Kim JW; Oh DY; Han SW; Lee SH; Kim DW; Im SA; Kim TY; Heo DS; Bang YJ
Am J Clin Oncol; 2012 Dec; 35(6):549-56. PubMed ID: 21659833
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcome and long-term survival of 150 consecutive patients with pancreatic neuroendocrine tumors: A comprehensive analysis by the World Health Organization 2010 grading classification.
Deng BY; Liu F; Yin SN; Chen AP; Xu L; Li B
Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):261-268. PubMed ID: 29307515
[TBL] [Abstract][Full Text] [Related]
14. Survival Analyses for Patients With Surgically Resected Pancreatic Neuroendocrine Tumors by World Health Organization 2010 Grading Classifications and American Joint Committee on Cancer 2010 Staging Systems.
Yang M; Ke NW; Zhang Y; Zeng L; Tan CL; Zhang H; Mai G; Tian BL; Liu XB
Medicine (Baltimore); 2015 Dec; 94(48):e2156. PubMed ID: 26632896
[TBL] [Abstract][Full Text] [Related]
15. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors.
Pape UF; Jann H; Müller-Nordhorn J; Bockelbrink A; Berndt U; Willich SN; Koch M; Röcken C; Rindi G; Wiedenmann B
Cancer; 2008 Jul; 113(2):256-65. PubMed ID: 18506737
[TBL] [Abstract][Full Text] [Related]
16. Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms?
Merola E; Rinke A; Partelli S; Gress TM; Andreasi V; Kollár A; Perren A; Christ E; Panzuto F; Pascher A; Jann H; Arsenic R; Cremer B; Kaemmerer D; Kump P; Lipp RW; Agaimy A; Wiedenmann B; Falconi M; Pavel ME
Ann Surg Oncol; 2020 May; 27(5):1348-1355. PubMed ID: 31720931
[TBL] [Abstract][Full Text] [Related]
17. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters.
Niederle MB; Hackl M; Kaserer K; Niederle B
Endocr Relat Cancer; 2010 Dec; 17(4):909-18. PubMed ID: 20702725
[TBL] [Abstract][Full Text] [Related]
18. Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509).
Capdevila J; Fazio N; Lopez C; Teulé A; Valle JW; Tafuto S; Custodio A; Reed N; Raderer M; Grande E; Garcia-Carbonero R; Jimenez-Fonseca P; Hernando J; Bongiovanni A; Spada F; Alonso V; Antonuzzo L; Spallanzani A; Berruti A; La Casta A; Sevilla I; Kump P; Giuffrida D; Merino X; Trejo L; Gajate P; Matos I; Lamarca A; Ibrahim T
J Clin Oncol; 2021 Jul; 39(20):2304-2312. PubMed ID: 33945297
[TBL] [Abstract][Full Text] [Related]
19. Recent Updates on Neuroendocrine Tumors From the Gastrointestinal and Pancreatobiliary Tracts.
Kim JY; Hong SM
Arch Pathol Lab Med; 2016 May; 140(5):437-48. PubMed ID: 27128301
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the concordance between the stage of the disease and Ki-67 proliferation index in gastroenteropancreatic neuroendocrine tumors.
Özaslan E; Demir S; Karaca H; Güven K
Eur J Gastroenterol Hepatol; 2016 Jul; 28(7):836-41. PubMed ID: 26945127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
